{"url":"https://lda.senate.gov/api/v1/filings/48cd718d-a4e9-41fa-91e7-e86d91b5e7b1/","filing_uuid":"48cd718d-a4e9-41fa-91e7-e86d91b5e7b1","filing_type":"RR","filing_type_display":"Registration","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/48cd718d-a4e9-41fa-91e7-e86d91b5e7b1/print/","filing_document_content_type":"text/html","income":null,"expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-03-10T10:10:59-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1310 G Street NW, Suite 680","registrant_address_2":null,"registrant_different_address":null,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401105973,"url":"https://lda.senate.gov/api/v1/registrants/401105973/","house_registrant_id":null,"name":"ALB SOLUTIONS","description":"​Strategic advisory firm.","address_1":"1310 G Street, NW","address_2":"Suite 680","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ADAM BUCKALEW","contact_telephone":"+1 202-579-2387","dt_updated":"2026-07-27T13:42:36.904847-04:00"},"client":{"id":71687,"url":"https://lda.senate.gov/api/v1/clients/71687/","client_id":71687,"name":"VERTEX PHARMACEUTICALS","general_description":"Biopharmaceutical company.","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-02-05"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Non-opioid pain relief and drug pipeline issues.","foreign_entity_issues":null,"lobbyists":[{"lobbyist":{"id":149504,"prefix":null,"prefix_display":null,"first_name":"VERONICA","nickname":null,"middle_name":null,"last_name":"JACKSON","suffix":null,"suffix_display":null},"covered_position":"Director, Strategic Planning, Office of the Assistant Secretary for Public Affairs, HHS","new":true},{"lobbyist":{"id":96147,"prefix":null,"prefix_display":null,"first_name":"ADAM","nickname":null,"middle_name":null,"last_name":"BUCKALEW","suffix":null,"suffix_display":null},"covered_position":"Covered Official Positions Continued: Deputy Chief of Staff, U.S. Rep. Markwayne Mullin (R-OK); Communications Director & Legislative Assistant, U.S. Rep. Gregg Harper (R-MS)","new":true}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}